Title: The efficacy and safety comparation between Nucleoside (acid) analogue initial combination and monotherapy in the treatment of chronic hepatitis B for 144 weeks
Abstract: Objective To compare the efficacy and safety of lamivudine and adefovir combined with entecavir initial monotherapy in the treatment of chronic hepatitis B for 144 weeks.Methods Collected 120 patients with chronic hepatitis initial treatment,which adefovir + lamivudine (LAM + ADV) initial combination group and entecavir (ETV) monotherapy treatment group for 144 weeks,60 cases respectively.Results After treated for 144 weeks LAM + ADV group beneath the 300copy/ml detection rate,HBeAg serum conversion rate and conversion rates were higher than ETV treatment group (P < 0.05),viral breakthrough rate was lower than the ETV group (P < 0.05),HBV-DNA and HBsAg compared with baseline decline in absolute terms and ALT normalization had no statistical difference between the two groups (P > 0.05),serum creatinine in two groups had no statistical difference,serum creatinine increased compared with baseline and differences were not statistically (P > 0.05).Conclusions Lamivudine and adefovir in the initial joint sustained virologic response,reducing HBV-DNA,HBeAg seroconversion and combined response rate was superior to entecavir monotherapy,both are similar in terms of renal safety.
Key words:
Lamivudine; Adefovir; Entecavir; Hepatitis B chronic; Antiviral agents
Publication Year: 2014
Publication Date: 2014-04-30
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot